Peginterferon–α2a (40 kDa) (Pegasys®) for hepatitis B

References

• EASL Jury. EASL International Consensus Conference on Hepatitis B. 13–14 September 2002: Geneva, Switzerland. Consensus statement (short version). J. Hepatol. 38, 533–540 (2003).
   PubMedGoogle Scholar
• Lee WM. Hepatitis B virus infection. N. Engl. J. Med. 33, 1733–1745 (1997).
   Google Scholar
• Perrillo RP, Mason AL. Therapy for hepatitis B virus infection. Gastroenterol. Clin. North Am. 23, 581–601 (1994).
   PubMed Web of Science ®Google Scholar
• Lai CL, Chien RN, Leung NW et al. A one year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339, 61–68 (1998).
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341, 1256–1263 (1999).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119, 172–180 (2000).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG et al. Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348, 808–816 (2003).
   PubMed Web of Science ®Google Scholar
• Wong D, Cheung R, O’Rourke K, Naylor C, Detsky A, Heathcote J. Effect of α-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann. Intern. Med. 114, 629–634 (1991).
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of pre-core mutant chronic hepatitis B. J. Viral Hepat. 8, 311–321 (2001).
   PubMed Web of Science ®Google Scholar
• Manesis EK, Hadziyannis SJ. Interferon-α treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 121, 101–109 (2001).
   PubMed Web of Science ®Google Scholar
• Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to α-interferon therapy? A statistical analysis of predictor factors. Hepatology 10, 761–763 (1989).
   PubMed Web of Science ®Google Scholar
• Schiff ER. Treatment algorithms for hepatitis B and C. Gut 34(Suppl. 2), S148–S149 (1993).
   PubMed Web of Science ®Google Scholar
• Tassopoulos NC, Volpes R, Pastore G et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 29, 889–896 (1999).
   PubMed Web of Science ®Google Scholar
• Leung N. Clinical experience with lamivudine. Semin. Liver Dis. 22(Suppl. 1), 15–21 (2002).
   PubMedGoogle Scholar
• Liaw YF, Chien RN, Yeh CT et al. Acute exacerbations and hepatitis B clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30, 567–572 (1999).
   PubMed Web of Science ®Google Scholar
• Lee CM, Ong GY, Lu SN et al. Durability of lamivudine induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J. Hepatol. 37, 669–674 (2002).
   PubMed Web of Science ®Google Scholar
• Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32, 803–806 (2000).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asians patients with chronic hepatitis B. Gastroenterology 119, 172–180 (2000).
   PubMed Web of Science ®Google Scholar
• Fung SK, Wong F, Hussain M, Lok ASF. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen negative chronic hepatitis B. J. Viral Hepat. 11, 432–438 (2004).
   PubMed Web of Science ®Google Scholar
• Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 15, 419–429 (2001).
   PubMed Web of Science ®Google Scholar
• Wang YS, Youngster S, Bausch J. Identification of the major positional isomer of pegylated interferon-α2b. Biochemistry 39, 10634–10640 (2000).
   PubMed Web of Science ®Google Scholar
• Pegasys (Peginterferon-α2a) solution for injection package insert. Roche Pharmaceuticals, NJ, USA, December 2002.
   Google Scholar
• Bailon P, Palleroni A, Schaffer CA et al. Rational design of a potent, long-lasting form on interferon: a 40 kDa branched polyethylene glycol-conjugated interferon-α2a for the treatment of hepatitis C. Bioconjug. Chem. 12, 195–202 (2001).
   PubMed Web of Science ®Google Scholar
• Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40, 539–551 (2001).
   PubMed Web of Science ®Google Scholar
• Lamb MW, Martin NE. Weight-based versus fixed dosing of peginterferon (40 kDa) α2a. Ann. Pharmacother. 36, 933–935 (2002).
   PubMed Web of Science ®Google Scholar
• Modi MW, Fulton JS, Buckmann DK et al. Clearance of pegylated (40 kDa) interferon α2a (PEGASYS) is primarily hepatic. Hepatology 32, 371A (2000).
   Web of Science ®Google Scholar
• Sen GC. Viruses and interferons. Ann. Rev. Microbiol. 55, 255–281 (2001).
   PubMed Web of Science ®Google Scholar
• Perry CM, Jarvis B. Peginterferon-α2a (40 kDa): a review of its use in the management of chronic hepatitis C. Drugs 61, 2263–2288 (2001).
   PubMed Web of Science ®Google Scholar
• Baron S, Tyring SK, Fleischmann WR Jr et al. The interferons. Mechanisms of action and clinical applications. J. Am. Med. Assoc. 266, 1375–1383 (1991).
   PubMed Web of Science ®Google Scholar
• Cirelli R, Tyring SK. Major therapeutics uses of interferons. Clin. Immunother. 3, 27–87 (1995).
   Google Scholar
• Cooksley WG, Piratvisuth T, Lee SD et al. Peginterferon α2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J. Viral. Hepat. 10, 298–305 (2003).
   PubMed Web of Science ®Google Scholar
• Perillo RP, Wright TL, Rakela J et al. Lamivudine North American Transplant Group. A multicenter United States–Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33, 424–432 (2001).
   PubMed Web of Science ®Google Scholar
• Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 30, 770–774 (1999).
   PubMed Web of Science ®Google Scholar
• Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon-α for chronic hepatitis B. N. Engl. J. Med. 334, 1422–1427 (1996).
   PubMed Web of Science ®Google Scholar
• Wong DK, Cheung AM, O’Rourke K, Naylor CD, Detsky AS, Heathcote EJ. Effect of α-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 119, 312–323 (1993).
   Google Scholar
• Wai CT, Chu CJ, Hussain M, Lok AS. HBV gentoype B is associated with a better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 36, 1425–1430 (2002).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Lau G, Bonino F et al. Peginterferon α2a alone, lamivudine alone and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351, 1206–1217 (2004).
   PubMed Web of Science ®Google Scholar
• Marcellin, Lau GK, Bonino F et al. Sustained response to peginterferon α2a (40 kDa) (PEGASYS) in HBeAg negative chronic hepatitis B. 1-year follow-up data from a large, randomized multinational study. J. Hepatol. 42, 185 (2005).
   Google Scholar
• Bonino F, Lau GK, Marcellin P et al. The first detailed analysis of predictors of response in HBeAg-negative chronic hepatitis B: data from a multicenter, randomized, partially double-blind study of peginterferon α2a (40 kDa) (PEGASYS) alone or in combination with lamivudine versus lamivudine alone. Hepatology 40(Suppl. 1), 659A (2004).
   Google Scholar
• Piratvisuth T, Marcellin P, Lau GK et al. ALT flares and sustained ALT response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon α2a (40 kD) (PEGASYS), peginterferon α2a plus lamivudine or lamivudine alone. Hepatology 40(Suppl. 1), 656A (2004).
   Google Scholar
• Lau GKK, Piratvisuth T, Luo KX et al. Peginterferon α2a (40 kDa) (PEGASYS®) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg-positive chronic hepatitis B: results from a large, multinational study. N. Engl. J. Med. 352, 2682–2695 (2005).
   Web of Science ®Google Scholar
• Germanidis G, Lau G, Marcellin P et al. Profound on-treatment viral suppression with peginterferon α2a (40 kDa) (Pegasys) plus lamivudine combination therapy limits the develoment of YMDD mutations, but does not improve sustained response rates over peginterferon α-2a (40 kD) alone. Hepatology 40(Suppl. 1), 633A (2004).
   Google Scholar
• Marcellin P, Lau GK, Piratvisuth T et al. Better safety and quality of life in patients with chronic hepatitis B than in patients with chronic hepatitis C when treated with peginterferon α2a (40 kDa) (PEGASYS). Hepatology 40(Suppl. 1), 668A (2004).
   Google Scholar
• Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D. Treatment of HBeAg negative chronic hepatitis B. Sem. Liver Dis. 23, 81–88 (2003).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Papatheodoridis GV. Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others). J. Hepatol. 39(Suppl. 1), S172–S176 (2003).
   Google Scholar
• Lau GK, Suri D, Liang R et al. Resolution of chronic hepatitis B and antiHBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 122, 614–624 (2002).
   PubMed Web of Science ®Google Scholar
• Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon α2a alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 365, 123–129 (2005).
   PubMed Web of Science ®Google Scholar
• Chan HL, Leung NW, Hui AY et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-α2b and lamivudine with lamivudine alone. Ann. Intern. Med. 142, 240–250 (2005).
   PubMed Web of Science ®Google Scholar
• Shaw T, Locarnini S. Combination chemotherapy for hepatitis B virus: the path forward? Drugs 60, 517–531 (2000).
   PubMed Web of Science ®Google Scholar